BBH:NSD-VanEck Vectors Biotech ETF

ETF | Health | NASDAQ Global Market

Last Closing Price

USD 115.08


-1.87 (-1.60)%

Market Cap

USD 0.40B



Average Target Price

Average Analyst Rating


STA Verdict



The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors? US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Inception Date: 20/12/2011

Primary Benchmark: MVIS US Listed Biotech 25 NR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.4%

Management Expense Ratio: 0.35 %

Unadjusted Closing Price

Adjusted Closing Price



Top Sectors


Top Regions


Share Volume

Relative Performance (Total Returns)

Relative Returns (From:    To: 2018-12-17 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
IBB iShares Nasdaq Biotechnology I.. 0.47 %

-1.68 (-1.65%)

USD 7.93B
PSCH Invesco S&P SmallCap Health Ca.. 0.29 %

-4.22 (-3.64%)

USD 1.01B
PPH VanEck Vectors Pharmaceutical .. 0.35 %

-1.28 (-2.20%)

USD 0.25B
PTH Invesco DWA Healthcare Momentu.. 0.60 %

-2.83 (-3.72%)

USD 0.22B
BTEC Principal Healthcare Innovator.. 0.42 %

-0.37 (-1.25%)

USD 0.05B
CNCR Loncar Cancer Immunotherapy ET.. 0.79 %

-0.73 (-3.59%)

USD 0.04B
FTXH First Trust Nasdaq Pharmaceuti.. 0.60 %

-0.30 (-1.48%)

USD 4.00M
GNRX VanEck Vectors Generic Drugs E.. 0.57 %

-0.01 (-0.07%)

USD 3.28M
SLIM The Obesity ETF 0.50 %

-0.88 (-2.70%)

USD 3.17M
LNGR Global X Longevity Thematic ET.. 0.52 %

-0.29 (-1.47%)


ETFs Containing BBH


Market Performance

  Market Performance vs.
Industry/Classification (Health)
Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Capital Gain -7.64% 27% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.64% 27% F 55% F
Trailing 12 Months  
Capital Gain -9.36% 18% F 55% F
Dividend Return 0.54% 56% F 9% F
Total Return -8.82% 18% F 52% F
Trailing 5 Years  
Capital Gain 37.80% 40% F 64% D
Dividend Return 1.62% 60% D- 4% F
Total Return 39.42% 40% F 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 7.73% 45% F 53% F
Dividend Return 8.01% 45% F 50% F
Total Return 0.28% 45% F 8% F
Risk Return Profile  
Volatility (Standard Deviation) 19.48% 27% F 64% D
Risk Adjusted Return 41.12% 36% F 53% F
Market Capitalization 0.58B 80% B- 55% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.